Loading clinical trials...
Loading clinical trials...
A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases
Conditions
Interventions
TG6002
Flucytosine (5-FC)
Locations
3
France
Centre Léon Bérard
Lyon, France
Institut Gustave Roussy
Villejuif, France
NHS St James's University Hospital
Leeds, United Kingdom
Start Date
January 17, 2020
Primary Completion Date
February 23, 2023
Completion Date
February 23, 2023
Last Updated
June 23, 2023
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Transgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions